insights_auto
Zakaj je tečaj LONA padel 34,87%?
Podrobneje raziščichevron_right
LONA:NASDAQ
LeonaBio Inc
3,25 $
arrow_downward
−34,87%(−1,74) 1D
3,33 $
arrow_upward
+2,46% (+0,080)bedtimePo zaprtju
Zaprto: 25. sep., 16:00:01 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za LONA …
Odpri
5,19 $
Visoka
5,60 $
Nizka
3,12 $
Tržna kapitalizacija
30,62 mio.
Povprečni promet
65,16 tis.
Promet
349,44 tis.
52-tedenski najvišji tečaj
14,19 $
52-tedenski najnižji tečaj
3,12 $
Čisti dobiček na delnico
−19,72 $
Beta
2,05
Št. izdanih delnic
9,42 mio.
Št. zaposlenih
19
Odpri
5,19 $
Visoka
5,60 $
Nizka
3,12 $
Tržna kapitalizacija
30,62 mio.
Povprečni promet
65,16 tis.
Promet
349,44 tis.
52-tedenski najvišji tečaj
14,19 $
52-tedenski najnižji tečaj
3,12 $
Čisti dobiček na delnico
−19,72 $
Beta
2,05
Št. izdanih delnic
9,42 mio.
Št. zaposlenih
19
Novice
Iz spletnih virov in novičarskih partnerjev
Benzinga
·
pred 14 urami
12 Health Care Stocks Moving In Friday's Intraday Session
The Globe and Mail
·
pred 2 dnevoma
LeonaBio Opens Warrant Exercise Window for New Capital
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Vizitka: LeonaBio Inc
Generalni direktor-
Št. zaposlenih19
Ustanovljeno2011
SedežBothell, Washington, Združene države Amerike
Sektor-
Spletno mestoleonabio.com